News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure announces filing of Clinical Trial Application with Polish regulator for OATD-02, a novel dual arginase inhibitor being developed for the treatment of cancer
11 August 2022
Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01
23 June 2022
OncoArendi Therapeutics Reports Continued Strategic and Operational Momentum for 12 Months ended 31 December 2021
25 March 2022
OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan
11 March 2022
OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr. Zbigniew Zasłona and Agnieszka Rajczuk-Szczepańska to its Management Board
31 January 2022
OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer
27 January 2022
Events & Presentations
Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada
27 February 2020
ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA
4 September 2019
EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018
17 September 2018